Changes

Jump to: navigation, search

Hereditary hemorrhagic telangiectasia

22 bytes added, 18:40, 14 December 2019
m
no edit summary
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/lary.20065 Yaniv et al. 2009]
| style="background-color:#1a9851" |Randomized Phase II (E-esc)
|[[#Placebo|Placebo]]
| style="background-color:#1a9850" |Superior frequency of epistaxis
|-
|[https://www.sciencedirect.com/science/article/pii/S0049384814003387 Geisthoff et al. 2014 (TAHHT)]
| style="background-color:#1a9851" |Phase III (E-esc)
|[[#Placebo|Placebo]]
| style="background-color:#ffffbf" |Seems not superior (*)
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1111/jth.12654 Gaillard et al. 2014 (ATERO)]
| style="background-color:#1a9851" |Phase III (E-esc)
|[[#Placebo|Placebo]]
| style="background-color:#1a9850" |Shorter mean duration of epistaxis
|-
|}
''Note: in TAHHT, the primary outcome of hemoglobin levels was not statistically significantly different, but the secondary outcome of epistaxis was superior for this arm.''
====Hemostasis therapy====
*[[Tranexamic acid (Cyklokapron)]]
LookupUsers, editors, emailconfirmed
24,702
edits

Navigation menu